Prokarium to present at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Livija Deban, Prokarium’s CEO, will be presenting at SITC 2022.
Title: Overcoming the suppressive microenvironment with a live bacterial immunotherapy
When/Where: November 11th, 2022; Poster Session

Related News

Prokarium Announces Upcoming Oral Presentations of Interim Clinical Data at the EAU and AUA 2026 Annual Meetings

London, UK – 16 February 2026 – Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapy for the treatment...

Prokarium appoints Ibs Mahmood as Chief Executive Officer

London, UK – November 11, 2025 – Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the...

Prokarium appoints Ibs Mahmood as Chief Executive Officer

London, UK – November 11, 2025 – Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the...

Prokarium expands IP portfolio with two new U.S. patents strengthening its position in bladder cancer

LONDON, United Kingdom, November 1, 2024 – Prokarium, a biopharmaceutical company developing innovative cancer treatments, today announced the...

Prokarium expands IP portfolio with two new U.S. patents strengthening its position in bladder cancer

LONDON, United Kingdom, November 1, 2024 – Prokarium, a biopharmaceutical company developing innovative cancer treatments, today announced the...